{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T08:57:36.619584+00:00","company":{"ticker":"IBIO","cik":1420720,"company_name":"iBio, Inc."},"pagination":{"limit":100,"returned":58,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Woodforest National Bank","detail":"credit_facility","count":9,"first_seen":"2023-02-21T23:59:59+00:00","last_seen":"2023-12-26T23:59:59+00:00","evidence_fact_ids":[85686,107527,112152,168211,168212,178106,178107,178108,178109]},{"display_name":"A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC","detail":"underwriting","count":1,"first_seen":"2023-12-06T23:59:59+00:00","last_seen":"2023-12-06T23:59:59+00:00","evidence_fact_ids":[89844]},{"display_name":"Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC","detail":"atm_program","count":1,"first_seen":"2026-02-27T23:59:59+00:00","last_seen":"2026-02-27T23:59:59+00:00","evidence_fact_ids":[30823]},{"display_name":"H.C. Wainwright & Co., LLC","detail":"underwriting","count":1,"first_seen":"2022-12-08T23:59:59+00:00","last_seen":"2022-12-08T23:59:59+00:00","evidence_fact_ids":[192377]},{"display_name":"Jefferies LLC","detail":"atm_program","count":1,"first_seen":"2026-02-27T23:59:59+00:00","last_seen":"2026-02-27T23:59:59+00:00","evidence_fact_ids":[30822]},{"display_name":"Lincoln Park Capital Fund, LLC","detail":"equity_purchase","count":1,"first_seen":"2023-08-04T23:59:59+00:00","last_seen":"2023-08-04T23:59:59+00:00","evidence_fact_ids":[123350]},{"display_name":"Loeb Term Solutions LLC","detail":"credit_facility","count":1,"first_seen":"2024-01-19T23:59:59+00:00","last_seen":"2024-01-19T23:59:59+00:00","evidence_fact_ids":[80612]},{"display_name":"Majestic Realty Co.","detail":"asset_purchase","count":1,"first_seen":"2023-09-21T23:59:59+00:00","last_seen":"2023-09-21T23:59:59+00:00","evidence_fact_ids":[112151]},{"display_name":"Otsuka Pharmaceutical Co., Ltd.","detail":"asset_purchase","count":1,"first_seen":"2024-02-26T23:59:59+00:00","last_seen":"2024-02-26T23:59:59+00:00","evidence_fact_ids":[72006]}],"lender":[{"display_name":"Loeb Term Solutions LLC","detail":"term_loan","count":1,"first_seen":"2024-01-19T23:59:59+00:00","last_seen":"2024-01-19T23:59:59+00:00","evidence_fact_ids":[80615]}],"ma_counterparty":[{"display_name":"Otsuka Pharmaceutical Co., Ltd.","detail":"disposition","count":1,"first_seen":"2024-02-26T23:59:59+00:00","last_seen":"2024-02-26T23:59:59+00:00","evidence_fact_ids":[72007]},{"display_name":"The Board of Regents of the Texas A&M University System","detail":"disposition","count":1,"first_seen":"2024-06-05T23:59:59+00:00","last_seen":"2024-06-05T23:59:59+00:00","evidence_fact_ids":[128776]}]},"facts":[{"fact_type":"earnings_release","fact_key":"89c8c7758aba96edf84d1fd12a58163a03ec49a7","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2026-05-12T20:15:50+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter ended Mar. 31, 2026","report_date":"2026-05-12","result_type":"reported_results","revenue_text":null},"claim":"iBio, Inc. reported financial results for third quarter ended Mar. 31, 2026.","evidence_excerpt":"On May 12, 2026, iBio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.","confidence":0.4,"filing_url":"https://secwatch.observer/filing/0001104659-26-059408","anchor_url":"https://secwatch.observer/filing/0001104659-26-059408#claim-89c8c7758aba96edf84d1fd12a58163a03ec49a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926059408/0001104659-26-059408-index.htm"},{"fact_type":"executive_change","fact_key":"f39774f2fc","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2026-05-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-05-07","interim":false,"role":"Class II director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dr. Elizabeth Stoner was appointed as Class II director at iBio, Inc..","evidence_excerpt":"On May 7, 2026, the Board of Directors (the “Board”) of iBio, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Elizabeth Stoner, M.D., M.S., to serve as a Class II director of the Company, effective May 7, 2026","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-26-057945","anchor_url":"https://secwatch.observer/filing/0001104659-26-057945#claim-f39774f2fc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926057945/0001104659-26-057945-index.htm"},{"fact_type":"executive_change","fact_key":"bb4a728ca5","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2026-05-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-05-07","interim":false,"role":"Member of the Board","role_category":"director","successor_name":"Dr. Elizabeth Stoner","successor_named":true},"claim":"Evert Schimmelpennink resigned as Member of the Board at iBio, Inc..","evidence_excerpt":"On May 7, 2026, Evert Schimmelpennink, a member of the Board, notified the Company of his decision to resign from the Board, including from his position as a member of the Compensation Committee of the Board, effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-26-057945","anchor_url":"https://secwatch.observer/filing/0001104659-26-057945#claim-bb4a728ca5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926057945/0001104659-26-057945-index.htm"},{"fact_type":"material_agreement","fact_key":"ac5ceaa7606f93dd2730c1b93de64bc96bb4277a","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2026-02-27T23:59:59+00:00","payload":{"action":"termination","agreement_name":"At Market Issuance Sales Agreement","agreement_type":"atm_program","counterparty":"Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC","effective_date":"2026-02-23","item_codes_triggered":["1.02"],"value_text":"aggregate offering price of up to $7,350,000"},"claim":"iBio, Inc. terminated At Market Issuance Sales Agreement with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC valued at aggregate offering price of up to $7,350,000 (effective 2026-02-23).","evidence_excerpt":"On February 23, 2026, the Company provided notice terminating the At Market Issuance Sales Agreement (the “Prior ATM Agreement”), dated July 3, 2024, between the Company and Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-021654","anchor_url":"https://secwatch.observer/filing/0001104659-26-021654#claim-ac5ceaa7606f93dd2730c1b93de64bc96bb4277a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926021654/0001104659-26-021654-index.htm"},{"fact_type":"material_agreement","fact_key":"d28554c81ac582fca68149f4fb80931e59cd317c","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2026-02-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Open Market Sale Agreement SM","agreement_type":"atm_program","counterparty":"Jefferies LLC","effective_date":"2026-02-27","item_codes_triggered":["1.01"],"value_text":"up to $100,000,000"},"claim":"iBio, Inc. entered into Open Market Sale Agreement SM with Jefferies LLC valued at up to $100,000,000 (effective 2026-02-27).","evidence_excerpt":"On February 27, 2026, iBio, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement SM (the “ATM Agreement”) with Jefferies LLC (“Jefferies”) providing for the sale by the Company of its shares of common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-021654","anchor_url":"https://secwatch.observer/filing/0001104659-26-021654#claim-d28554c81ac582fca68149f4fb80931e59cd317c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926021654/0001104659-26-021654-index.htm"},{"fact_type":"equity_issuance","fact_key":"586f7a62a03e236ff13e755b954ec20e30f285b9","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2026-01-12T23:59:59+00:00","payload":{"action":"warrant_issuance","consideration_text":"purchase price per pre-funded warrant of $2.349 (equal to share price minus $0.001 exercise price)","effective_date":"2026-01-08","item_codes_triggered":["3.02"],"purchaser":"institutional investors","security_type":"warrant","shares_text":"pre-funded warrants to purchase up to 9,653,257 shares of common stock"},"claim":"iBio, Inc. issued pre-funded warrants to purchase up to 9,653,257 shares of common stock of warrant to institutional investors for purchase price per pre-funded warrant of $2.349 (equal to share price minus $0.001 exercise price).","evidence_excerpt":"On January 8, 2026, iBio, Inc., a Delaware company (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a private placement priced at-the-market consistent with the rules of the Nasdaq Stock Market LLC (the “Private Placement”) an aggregate of 1,408,481 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and, in lieu of Shares, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 9,653,257 shares of Common Stock (the “Pre-Funded Warrant Shares”).","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001104659-26-002940","anchor_url":"https://secwatch.observer/filing/0001104659-26-002940#claim-586f7a62a03e236ff13e755b954ec20e30f285b9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/0001104659-26-002940-index.htm"},{"fact_type":"equity_issuance","fact_key":"daa6d533cf7d21f8ce477118afb646aff2feca03","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2026-01-12T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"purchase price per share of $2.35; aggregate gross proceeds approx. $26 million","effective_date":"2026-01-08","item_codes_triggered":["3.02"],"purchaser":"institutional investors","security_type":"common_stock","shares_text":"1,408,481 shares of common stock"},"claim":"iBio, Inc. issued 1,408,481 shares of common stock of common stock to institutional investors for purchase price per share of $2.35; aggregate gross proceeds approx. $26 million.","evidence_excerpt":"warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 9,653,257 shares of Common\nStock (the “Pre-Funded Warrant Shares”). The purchase price per Share is $2.35. The purchase price per Pre-Funded Warrant\nis $2.349, which is equal to the purchase price per Share, minus the exercise price of $0.001 for each Pre-Funded Warrant. The Private","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001104659-26-002940","anchor_url":"https://secwatch.observer/filing/0001104659-26-002940#claim-daa6d533cf7d21f8ce477118afb646aff2feca03","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/0001104659-26-002940-index.htm"},{"fact_type":"material_agreement","fact_key":"681f0fe0849cfa507a902ab1c072ee3c5507d2ee","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2026-01-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain institutional investors","effective_date":"2026-01-08","item_codes_triggered":["1.01"],"value_text":"approximately $26 million"},"claim":"iBio, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $26 million (effective 2026-01-08).","evidence_excerpt":"On January 8, 2026, iBio, Inc., a Delaware company (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a private placement priced at-the-market consistent with the rules of the Nasdaq Stock Market LLC (the “Private Placement”) an aggregate of 1,408,481 shares (the “Shares”) of the Company’s common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-002940","anchor_url":"https://secwatch.observer/filing/0001104659-26-002940#claim-681f0fe0849cfa507a902ab1c072ee3c5507d2ee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/0001104659-26-002940-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"d0678d240c24734cccf6fa3c54c9d675c48dd6d1","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2025-08-01T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2026-01-26","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"$1.00","notice_date":"2025-07-29","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"iBio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"July 29, 2025, iBio, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (June 13, 2025 to July 28, 2025), the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”), as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The Nasdaq Capital Market","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-25-009992","anchor_url":"https://secwatch.observer/filing/0001558370-25-009992#claim-d0678d240c24734cccf6fa3c54c9d675c48dd6d1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000155837025009992/0001558370-25-009992-index.htm"},{"fact_type":"ma_transaction","fact_key":"a68a3cdd736f7500fdfd9596f2d7b00d4d824f66","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2024-06-05T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2024-05-31","consideration_text":"$8,500,000","counterparty":"The Board of Regents of the Texas A&M University System","effective_date":"2024-05-31","item_codes_triggered":["2.01"]},"claim":"iBio, Inc. completed a disposition involving The Board of Regents of the Texas A&M University System for $8,500,000 (closed 2024-05-31).","evidence_excerpt":"and together with the Ground Lease, Improvements and Personal Property, collectively, the “Property”). Pursuant to the Purchase and Sale Agreement, iBio CDMO received $8,500,000 from The Board of Regents upon the closing of the sale of Property, which was paid to the Lender as described above. The foregoing description of the Purchase and Sale Agreement","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-24-000027","anchor_url":"https://secwatch.observer/filing/0001420720-24-000027#claim-a68a3cdd736f7500fdfd9596f2d7b00d4d824f66","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000027/0001420720-24-000027-index.htm"},{"fact_type":"earnings_release","fact_key":"4af20ee1212125d2aa40f1f7a73cd49d11f428e1","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter ended March 31, 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":null},"claim":"iBio, Inc. reported financial results for third quarter ended March 31, 2024.","evidence_excerpt":"On May 13, 2024, iBio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001420720-24-000018","anchor_url":"https://secwatch.observer/filing/0001420720-24-000018#claim-4af20ee1212125d2aa40f1f7a73cd49d11f428e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000018/0001420720-24-000018-index.htm"},{"fact_type":"material_agreement","fact_key":"62b67157dc09b171d94a81b5dc6e32b348e1927e","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"several institutional investors and an accredited investor","effective_date":"2024-03-26","item_codes_triggered":["1.01"],"value_text":"gross proceeds of approximately $15.1 million"},"claim":"iBio, Inc. entered into Purchase Agreement with several institutional investors and an accredited investor valued at gross proceeds of approximately $15.1 million (effective 2024-03-26).","evidence_excerpt":"On March 26, 2024, iBio, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with several institutional investors and an accredited investor (the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of the following securities for gross proceeds of approximately $15.1 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-24-000015","anchor_url":"https://secwatch.observer/filing/0001420720-24-000015#claim-62b67157dc09b171d94a81b5dc6e32b348e1927e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000015/0001420720-24-000015-index.htm"},{"fact_type":"ma_transaction","fact_key":"6367b8e78a7d1e8345b482d346012726fc986bb4","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2024-02-26T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2024-02-25","consideration_text":"$1,000,000 paid at closing","counterparty":"Otsuka Pharmaceutical Co., Ltd.","effective_date":"2024-02-25","item_codes_triggered":["2.01"]},"claim":"iBio, Inc. completed a disposition involving Otsuka Pharmaceutical Co., Ltd. for $1,000,000 paid at closing (closed 2024-02-25).","evidence_excerpt":"and assumed, all intellectual property rights directly related to the Company’s PD-1 agonist assets (the “PD-1 Assets”) developed or held for development in consideration of $1,000,000 paid at closing (the “Closing Consideration”).  The Purchase Agreement also provides for a potential contingent payment of $2,500,000 upon the achievement of specified","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-24-000012","anchor_url":"https://secwatch.observer/filing/0001420720-24-000012#claim-6367b8e78a7d1e8345b482d346012726fc986bb4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000012/0001420720-24-000012-index.htm"},{"fact_type":"material_agreement","fact_key":"9d5e3c37df13822a0d87e5f0af076efcb2576b35","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2024-02-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Asset Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Otsuka Pharmaceutical Co., Ltd.","effective_date":"2024-02-25","item_codes_triggered":["1.01"],"value_text":"$1,000,000 paid at closing"},"claim":"iBio, Inc. entered into Asset Purchase Agreement with Otsuka Pharmaceutical Co., Ltd. valued at $1,000,000 paid at closing (effective 2024-02-25).","evidence_excerpt":"On February 25, 2024, iBio, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”) pursuant to which the Company sold and assigned to Otsuka, and Otsuka purchased and assumed, all intellectual property rights directly related to the Company’s PD-1 agonist assets (the “PD-1 Assets”) developed or held for development in consideration of $1,000,000 paid at closing (the “Closing Consideration”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-24-000012","anchor_url":"https://secwatch.observer/filing/0001420720-24-000012#claim-9d5e3c37df13822a0d87e5f0af076efcb2576b35","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000012/0001420720-24-000012-index.htm"},{"fact_type":"auditor_change","fact_key":"c6eb42b5c0f4055a3660cba3762e3a63fcf342c2","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2024-02-21T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Grassi & Co., CPAs, P.C.","disagreement_text":null,"effective_date":"2024-02-20","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"iBio, Inc. engaged Grassi & Co., CPAs, P.C. as its auditor.","evidence_excerpt":"On February 20, 2024, the Company entered into an engagement letter with Grassi and engaged Grassi as the Company’s independent registered public accounting firm effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-24-000008","anchor_url":"https://secwatch.observer/filing/0001420720-24-000008#claim-c6eb42b5c0f4055a3660cba3762e3a63fcf342c2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000008/0001420720-24-000008-index.htm"},{"fact_type":"auditor_change","fact_key":"e7ae8e6ed4f30268aeee42d4794d91c86d8016e1","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2024-02-21T23:59:59+00:00","payload":{"action":"resignation","auditor_name":"CohnReznick LLP","disagreement_text":null,"effective_date":"2024-02-15","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"CohnReznick LLP resigned as auditor of iBio, Inc..","evidence_excerpt":"On February 15, 2024, the Company was notified that its independent registered public accounting firm, CohnReznick LLP (\"CohnReznick\"), is resigning its engagement with the Company effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-24-000008","anchor_url":"https://secwatch.observer/filing/0001420720-24-000008#claim-e7ae8e6ed4f30268aeee42d4794d91c86d8016e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000008/0001420720-24-000008-index.htm"},{"fact_type":"debt_financing","fact_key":"0a332ec407e8d794ab92e311f185647bc83d8b97","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"counterparty":"Loeb Term Solutions LLC","effective_date":"2024-01-16","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"Prime Rate, as quoted in the Wall Street Journal plus 8.5%","item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"$1,071,572"},"claim":"iBio, Inc. incurred term loan of $1,071,572 with Loeb Term Solutions LLC at Prime Rate, as quoted in the Wall Street Journal plus 8.5%.","evidence_excerpt":"On January 16, 2024, iBio, Inc. (the “Company”), entered into a credit and security agreement (the “Credit and Security Agreement”) with Loeb Term Solutions LLC, an Illinois limited liability company (“Lender”), for a term loan or equipment line of credit loan (the “Loan”) pursuant to which the Company issued to Lender a term promissory note in the principal amount of $1,071,572 (the “Term Note”) bearing interest at the Prime Rate, as quoted in the Wall Street Journal plus 8.5% (the “Effective Rate”), for proceeds of $1,027,455.23 after payment of $42,862.88 to Lender as an origination fee, $1,172.89 for appraisal costs, and $75.00 for bank wire fees.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-24-000005","anchor_url":"https://secwatch.observer/filing/0001420720-24-000005#claim-0a332ec407e8d794ab92e311f185647bc83d8b97","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000005/0001420720-24-000005-index.htm"},{"fact_type":"material_agreement","fact_key":"88189a7b312606432f1f6c1f9155fc63e94309c3","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Credit and Security Agreement","agreement_type":"credit_facility","counterparty":"Loeb Term Solutions LLC","effective_date":"2024-01-16","item_codes_triggered":["1.01"],"value_text":"$1,071,572"},"claim":"iBio, Inc. entered into Credit and Security Agreement with Loeb Term Solutions LLC valued at $1,071,572 (effective 2024-01-16).","evidence_excerpt":"On January 16, 2024, iBio, Inc. (the “Company”), entered into a credit and security agreement (the “Credit and Security Agreement”) with Loeb Term Solutions LLC, an Illinois limited liability company (“Lender”), for a term loan or equipment line of credit loan (the “Loan”) pursuant to which the Company issued to Lender a term promissory note in the principal amount of $1,071,572","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-24-000005","anchor_url":"https://secwatch.observer/filing/0001420720-24-000005#claim-88189a7b312606432f1f6c1f9155fc63e94309c3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000005/0001420720-24-000005-index.htm"},{"fact_type":"material_agreement","fact_key":"9b00cfd9b79ebdcf9775476783ad38737992bf78","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-12-26T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Eighth Amendment","agreement_type":"credit_facility","counterparty":"Woodforest National Bank","effective_date":"2023-12-22","item_codes_triggered":["1.01"],"value_text":null},"claim":"iBio, Inc. amended Eighth Amendment with Woodforest National Bank (effective 2023-12-22).","evidence_excerpt":"On December 22, 2023, iBio CDMO LLC (“Borrower”), a wholly owned subsidiary of iBio, Inc. (the “Company”) and Woodforest National Bank (“Woodforest”) entered into the Eighth Amendment (the “Eight Amendment”) to the Credit Agreement","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000072","anchor_url":"https://secwatch.observer/filing/0001420720-23-000072#claim-9b00cfd9b79ebdcf9775476783ad38737992bf78","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000072/0001420720-23-000072-index.htm"},{"fact_type":"material_agreement","fact_key":"572915f690f05399a7989880403765dcbe1ca3af","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-12-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Placement Agency Agreement","agreement_type":"underwriting","counterparty":"A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC","effective_date":"2023-12-05","item_codes_triggered":["1.01"],"value_text":"5.5% of the gross proceeds"},"claim":"iBio, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC valued at 5.5% of the gross proceeds (effective 2023-12-05).","evidence_excerpt":"On December 5, 2023, the Company entered into a placement agency agreement (the “ Placement Agency Agreement ”) with A.G.P./Alliance Global Partners (“ A.G.P. ”), as lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC (“ Brookline ”), as co-placement agent (A.G.P. and Brookline are referred to herein, collectively, as the “ Placement Agents ”), pursuant to which the Placement Agents agreed to serve as the placement agents for the Company on a “reasonable efforts basis” for the issuance and sale of the Shares and Warrants.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-123841","anchor_url":"https://secwatch.observer/filing/0001104659-23-123841#claim-572915f690f05399a7989880403765dcbe1ca3af","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465923123841/0001104659-23-123841-index.htm"},{"fact_type":"material_agreement","fact_key":"be0b66cf2224f470f9f4c4d93a2665aebe5df649","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-12-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain purchaser (the \"Purchasers\")","effective_date":"2023-12-05","item_codes_triggered":["1.01"],"value_text":"approximately $3.6 million"},"claim":"iBio, Inc. entered into Purchase Agreement with certain purchaser (the \"Purchasers\") valued at approximately $3.6 million (effective 2023-12-05).","evidence_excerpt":"On December 5, 2023, iBio, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement with certain purchaser (the “ Purchasers ”) identified on the signature pages thereto (the “ Purchase Agreement ”), pursuant to which the Company agreed to issue and sell, in a public offering (the “ Offering ”), (i) 600,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), (ii) 1,650,000 pre-funded warrants","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-123841","anchor_url":"https://secwatch.observer/filing/0001104659-23-123841#claim-be0b66cf2224f470f9f4c4d93a2665aebe5df649","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465923123841/0001104659-23-123841-index.htm"},{"fact_type":"governance_change","fact_key":"77472ee73845f84315f38f60486bc2aff0da3961","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-11-28T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-11-28","item_codes_triggered":["5.03"],"summary_text":"Certificate of Incorporation amended to effect a 1-for-20 reverse stock split, effective November 29, 2023."},"claim":"iBio, Inc.: Certificate of Incorporation amended to effect a 1-for-20 reverse stock split, effective November 29, 2023 (effective 2023-11-28).","evidence_excerpt":"On November 28, 2023, the Company filed an amendment to the Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the reverse stock split, with an effective time of 12:01 a.m. Eastern Time on November 29, 2023 (the “Reverse Stock Split”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000065","anchor_url":"https://secwatch.observer/filing/0001420720-23-000065#claim-77472ee73845f84315f38f60486bc2aff0da3961","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm"},{"fact_type":"shareholder_vote","fact_key":"43b9c7e9d6cfa0f3fa707988f0815abab24513ec","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-11-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-11-27","outcome":"passed","proposal_text":"Approval of adjournment of the 2023 Annual Meeting","proposal_type":"other","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"941,984","votes_against":"3,980,414","votes_for":"6,632,400","votes_withheld":null}]},"claim":"iBio, Inc. shareholders approved Approval of adjournment of the 2023 Annual Meeting at the 2023-11-27 meeting.","evidence_excerpt":"The stockholders approved the adjournment of the 2023 Annual Meeting, based on the votes set forth below; however, an adjournment was not needed as Proposals 4 and 5 received a sufficient number of votes for approval.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000065","anchor_url":"https://secwatch.observer/filing/0001420720-23-000065#claim-43b9c7e9d6cfa0f3fa707988f0815abab24513ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e2901a52262a6d3ef98887b9f16f52e6eb315870","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-11-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-11-27","outcome":"passed","proposal_text":"Adoption of the 2023 Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"7,402,650","subject":null,"votes_abstain":"121,966","votes_against":"1,518,849","votes_for":"2,511,333","votes_withheld":null}]},"claim":"iBio, Inc. shareholders approved Adoption of the 2023 Plan at the 2023-11-27 meeting.","evidence_excerpt":"The stockholders approved the adoption of the 2023 Plan.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000065","anchor_url":"https://secwatch.observer/filing/0001420720-23-000065#claim-e2901a52262a6d3ef98887b9f16f52e6eb315870","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm"},{"fact_type":"shareholder_vote","fact_key":"90c8f86dc56b18b824afb312c9aad682f29af0ba","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-11-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-11-27","outcome":"passed","proposal_text":"Approval of amendment to Certificate of Incorporation for reverse stock split range of 1-for-5 to 1-for-20","proposal_type":"charter_amendment","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"472,505","votes_against":"5,247,653","votes_for":"5,834,640","votes_withheld":null}]},"claim":"iBio, Inc. shareholders approved Approval of amendment to Certificate of Incorporation for reverse stock split range of 1-for-5 to 1-for-20 at the 2023-11-27 meeting.","evidence_excerpt":"The stockholders approved an amendment to the Company’s Certificate of Incorporation, at a ratio of 1-for-5 to 1-for-20 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board and included in a public announcement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000065","anchor_url":"https://secwatch.observer/filing/0001420720-23-000065#claim-90c8f86dc56b18b824afb312c9aad682f29af0ba","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9f0f539435287caddb0feeecb0422306ab44a779","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-11-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-11-27","outcome":"passed","proposal_text":"Advisory vote on executive compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"7,402,650","subject":null,"votes_abstain":"231,419","votes_against":"1,246,584","votes_for":"2,674,145","votes_withheld":null}]},"claim":"iBio, Inc. shareholders approved Advisory vote on executive compensation at the 2023-11-27 meeting.","evidence_excerpt":"The stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers (\"say-on-pay\"), as disclosed in the Definitive Proxy Statement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000065","anchor_url":"https://secwatch.observer/filing/0001420720-23-000065#claim-9f0f539435287caddb0feeecb0422306ab44a779","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c16215e87b6566727e8663f006eda9a70c88e27e","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-11-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-11-27","outcome":"passed","proposal_text":"Ratification of CohnReznick LLP as independent registered public accounting firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"182,697","votes_against":"1,989,566","votes_for":"9,382,535","votes_withheld":null}]},"claim":"iBio, Inc. shareholders approved Ratification of CohnReznick LLP as independent registered public accounting firm at the 2023-11-27 meeting.","evidence_excerpt":"The stockholders ratified the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the year ending June 30, 2024 based on the votes set forth below:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000065","anchor_url":"https://secwatch.observer/filing/0001420720-23-000065#claim-c16215e87b6566727e8663f006eda9a70c88e27e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c6a806e25f1823dbdeda2233b7d7d3128d697a64","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-11-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-11-27","outcome":"passed","proposal_text":"Election of two Class III directors","proposal_type":"director_election","results":[{"broker_non_votes":"7,402,650","subject":"William D. Clark","votes_abstain":null,"votes_against":null,"votes_for":"3,192,312","votes_withheld":"959,836"},{"broker_non_votes":"7,402,650","subject":"Gary Sender","votes_abstain":null,"votes_against":null,"votes_for":"3,094,901","votes_withheld":"1,057,247"}]},"claim":"iBio, Inc. shareholders approved Election of two Class III directors at the 2023-11-27 meeting.","evidence_excerpt":"The following two (2) nominees named as Class III directors of the Company’s Board of Directors, each to serve a three-year term expiring at the 2026 Annual Meeting of Stockholders and until such director’s successor is duly elected and qualified, were elected with the following votes:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000065","anchor_url":"https://secwatch.observer/filing/0001420720-23-000065#claim-c6a806e25f1823dbdeda2233b7d7d3128d697a64","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm"},{"fact_type":"material_agreement","fact_key":"c273586e95bc120e7a6524db0a44705be84db29c","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-10-10T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Seventh Amendment to the Credit Agreement","agreement_type":"credit_facility","counterparty":"Woodforest National Bank","effective_date":"2023-10-04","item_codes_triggered":["1.01"],"value_text":"Withdrawal of up to $1,000,000 on Oct 4, 2023 (minimum balance $2,000,000 until Oct 16); additional"},"claim":"iBio, Inc. amended Seventh Amendment to the Credit Agreement with Woodforest National Bank valued at Withdrawal of up to $1,000,000 on Oct 4, 2023 (minimum balance $2,000,000 until Oct 16); additional (effective 2023-10-04).","evidence_excerpt":"On October 4, 2023, iBio CDMO LLC (“Borrower”), a wholly owned subsidiary of iBio, Inc. (the “Company”) and Woodforest National Bank (“Woodforest”) entered into the Seventh Amendment to the Credit Agreement, which was entered into on November 1, 2021, as previously amended as of October 11, 2022, February 9, 2023, February 20, 2023, March 24, 2023, May 10, 2023 and September 18, 2023 (the “Credit Agreement”), which amendment among other things, permits the Company, in each case, so long as no Potential Default or Default (as such terms are defined in the Credit Agreement) to make the following withdrawals from the Reserve Funds Deposit Account (as defined in the Credit Agreement): (i) up to $1,000,000 on October 4, 2023 so long as Borrower maintains a minimum balance of $2,000,000 until October 16, 2023, (ii) up to an additional $750,000 after October 16, 2023 so long as Borrower maintains a minimum balance of $1,250,000 until November 13, 2023, and (iii) up to an additional $250,000 a","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-23-000054","anchor_url":"https://secwatch.observer/filing/0001420720-23-000054#claim-c273586e95bc120e7a6524db0a44705be84db29c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000054/0001420720-23-000054-index.htm"},{"fact_type":"earnings_release","fact_key":"c4b3833cc000d07b2ec0081b703071282038827a","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-09-27T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fiscal year ended June 30, 2023","report_date":"2023-09-27","result_type":"reported_results","revenue_text":null},"claim":"iBio, Inc. reported financial results for fiscal year ended June 30, 2023.","evidence_excerpt":"On September 27, 2023, iBio, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended June 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000048","anchor_url":"https://secwatch.observer/filing/0001420720-23-000048#claim-c4b3833cc000d07b2ec0081b703071282038827a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000048/0001420720-23-000048-index.htm"},{"fact_type":"earnings_release","fact_key":"acfed2b7cec3617cd77dcfa87a4abe5652ce289a","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-09-21T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss from continuing operations for the twelve months ending June 30, 2023, to be between $29.0 million and $29.5 mi","period_text":"the twelve months ending June 30, 2023","report_date":"2023-06-30","result_type":"preliminary_results","revenue_text":null},"claim":"iBio, Inc. reported the twelve months ending June 30, 2023 results: net income net loss from continuing operations for the twelve months ending June 30, 2023, to be between $29.0 million and $29.5 mi.","evidence_excerpt":"The Company expects net loss from continuing operations for the twelve months ending June 30, 2023, to be between $29.0 million and $29.5 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000041","anchor_url":"https://secwatch.observer/filing/0001420720-23-000041#claim-acfed2b7cec3617cd77dcfa87a4abe5652ce289a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000041/0001420720-23-000041-index.htm"},{"fact_type":"material_agreement","fact_key":"db3abd28a6b6fc1de1554019e4c3baef710f5dd7","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-09-21T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Sixth Amendment to Credit Agreement","agreement_type":"credit_facility","counterparty":"Woodforest National Bank","effective_date":"2023-09-18","item_codes_triggered":["1.01"],"value_text":null},"claim":"iBio, Inc. entered into Sixth Amendment to Credit Agreement with Woodforest National Bank (effective 2023-09-18).","evidence_excerpt":"On September 18, 2023, iBio CDMO and Woodforest National Bank entered into the Sixth Amendment (the “Sixth Amendment”) to that certain Credit Agreement, dated November 1, 2021, as previously amended as of October 11, 2022, February 9, 2023, February 20, 2023, March 24, 2023 and May 10, 2023 (the “Credit Agreement”), to amend the Credit Agreement to: (i) set the maturity date of the term loan to the earlier of (a) December 31, 2023, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement, (ii) provide that iBio CDMO will, immediately upon receipt of the proceeds of the sale of the Property, apply the net proceeds to satisfy all outstanding obligations under the term loan, and to the extent such net proceeds are sufficient, to pay off the term loan, and (iii) change the annual filing requirement solely for the fiscal year ending June 30, 2023, such that the filing is acceptable with or without a “going concern” designation; provided that (a) iBio CDMO","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001420720-23-000041","anchor_url":"https://secwatch.observer/filing/0001420720-23-000041#claim-db3abd28a6b6fc1de1554019e4c3baef710f5dd7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000041/0001420720-23-000041-index.htm"},{"fact_type":"material_agreement","fact_key":"4189e2f3386b6b239e52a845d5c51032dac61cc8","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-09-21T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase and Sale Agreement","agreement_type":"asset_purchase","counterparty":"Majestic Realty Co.","effective_date":"2023-09-15","item_codes_triggered":["1.01"],"value_text":"$17,250,000"},"claim":"iBio, Inc. entered into Purchase and Sale Agreement with Majestic Realty Co. valued at $17,250,000 (effective 2023-09-15).","evidence_excerpt":"On September 15, 2023, iBio CDMO LLC (“iBio CDMO”), a subsidiary of iBio, Inc. (the “Company”), entered into a purchase and sale agreement, dated as of September 15, 2023 (the “Purchase and Sale Agreement”) with Majestic Realty Co., a California corporation (“Majestic Realty”), pursuant to which iBio CDMO agreed to sell to Majestic Realty its cGMP biologics manufacturing facility located in Bryan, TX consisting of: (i) the ground leasehold estate and interest held under the Ground Lease Agreement, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015, between iBio CDMO (as assignee from College Station Investors LLC) and The Board of Regents of the Texas A&M University System (together, the “Ground Lease”), related to 21.401 acres in Brazos County, Texas land (the “Land”); (ii) the buildings, parking areas, improvements, and fixtures situated on the Land (the “Improvements”); (iii) all iBio CDMO’s right, title,","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001420720-23-000041","anchor_url":"https://secwatch.observer/filing/0001420720-23-000041#claim-4189e2f3386b6b239e52a845d5c51032dac61cc8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000041/0001420720-23-000041-index.htm"},{"fact_type":"earnings_release","fact_key":"3701913d8ea0a5f2902e2e71a2dd4d946cac10c5","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-08-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss from continuing operations ... to be between $29.0 million and $29.5 million","period_text":"twelve months ending June 30, 2023","report_date":"2023-06-30","result_type":"preliminary_results","revenue_text":null},"claim":"iBio, Inc. reported twelve months ending June 30, 2023 results: net income net loss from continuing operations ... to be between $29.0 million and $29.5 million.","evidence_excerpt":"On a preliminary unaudited basis, the Company expects net loss from continuing operations for the twelve months ending June 30, 2023, to be between $29.0 million and $29.5 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-088326","anchor_url":"https://secwatch.observer/filing/0001104659-23-088326#claim-3701913d8ea0a5f2902e2e71a2dd4d946cac10c5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465923088326/0001104659-23-088326-index.htm"},{"fact_type":"material_agreement","fact_key":"d2b08a99df7c1f44e3cadd46e81788d5a5c90f76","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-08-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Lincoln Park Capital Fund, LLC","effective_date":"2023-08-04","item_codes_triggered":["1.01"],"value_text":"up to $10.0 million"},"claim":"iBio, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $10.0 million (effective 2023-08-04).","evidence_excerpt":"On August 4, 2023, iBio, Inc. (the “Company”) entered into a purchase agreement, dated as of August 4, 2023 (the “Purchase Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which, under the terms and subject to the satisfaction of specified conditions set forth therein, the Company may sell to Lincoln Park up to $10.0 million (subject to certain limitations) of the Company’s common stock, par value $.001 per share (the “Common Stock”), from time to time during the term of the Purchase Agreement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-087894","anchor_url":"https://secwatch.observer/filing/0001104659-23-087894#claim-d2b08a99df7c1f44e3cadd46e81788d5a5c90f76","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465923087894/0001104659-23-087894-index.htm"},{"fact_type":"executive_change","fact_key":"56c9f8a9fd","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-06-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-06-22","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Martin Brenner was appointed as Chief Executive Officer at iBio, Inc..","evidence_excerpt":"appointed Dr. Martin Brenner its then Interim Chief Executive Officer (CEO), to the position of permanent CEO effective immediately","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-23-000033","anchor_url":"https://secwatch.observer/filing/0001420720-23-000033#claim-56c9f8a9fd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000033/0001420720-23-000033-index.htm"},{"fact_type":"material_agreement","fact_key":"1005f66b30aa21f0c5595e39525de966572661a4","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Fourth Amendment to the Guaranty","agreement_type":"credit_facility","counterparty":"Woodforest National Bank","effective_date":"2023-03-24","item_codes_triggered":["1.01"],"value_text":"Liquidity covenant reduced from $7,500,000 to $1,000,000"},"claim":"iBio, Inc. entered into Fourth Amendment to the Guaranty with Woodforest National Bank valued at Liquidity covenant reduced from $7,500,000 to $1,000,000 (effective 2023-03-24).","evidence_excerpt":"In addition, on March 24, 2023, the Company, as guarantor, entered into the Fourth Amendment to the Guaranty, which was executed on November 1, 2021, as amended (the “Guaranty”), which reduced the Liquidity Covenant (as defined in the Credit Agreement, which required the Company to maintain a certain level of unrestricted cash) from $7,500,000 to $1,000,000.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-23-000022","anchor_url":"https://secwatch.observer/filing/0001420720-23-000022#claim-1005f66b30aa21f0c5595e39525de966572661a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000022/0001420720-23-000022-index.htm"},{"fact_type":"material_agreement","fact_key":"b619e2b816bb99fd6c2458aa8f5faa8abbd8d40e","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Fourth Amendment to the Credit Agreement","agreement_type":"credit_facility","counterparty":"Woodforest National Bank","effective_date":"2023-03-24","item_codes_triggered":["1.01"],"value_text":"$2,000,000 retained of Fraunhofer settlement funds; $75,000 fee on closing or Maturity Date; liquidi"},"claim":"iBio, Inc. entered into Fourth Amendment to the Credit Agreement with Woodforest National Bank valued at $2,000,000 retained of Fraunhofer settlement funds; $75,000 fee on closing or Maturity Date; liquidi (effective 2023-03-24).","evidence_excerpt":"On March 24, 2023, iBio CDMO LLC, a wholly owned subsidiary of iBio, Inc. (the “Company”) and Woodforest National Bank (“Woodforest”) entered into the Fourth Amendment to the Credit Agreement (the “Fourth Amendment”) that was entered into on November 1, 2021, as amended (the “Credit Agreement”), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from 40% to 20%, and (iii) allow the Company to retain $2,000,000 million of the $5,100,000 million that the Company received from Fraunhofer USA Inc. (“Fraunhofer”) as part of its legal settlement with them (the “Fraunhofer Settlement Funds”), with the remaining $3,000,000 million being held in a Company account at Woodforest.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-23-000022","anchor_url":"https://secwatch.observer/filing/0001420720-23-000022#claim-b619e2b816bb99fd6c2458aa8f5faa8abbd8d40e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000022/0001420720-23-000022-index.htm"},{"fact_type":"material_agreement","fact_key":"466d8c37a403e4054bcf6779800b939e5a493b69","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-02-21T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Third Amendment to the Guaranty","agreement_type":"credit_facility","counterparty":"Woodforest National Bank","effective_date":"2023-02-20","item_codes_triggered":["1.01"],"value_text":null},"claim":"iBio, Inc. amended Third Amendment to the Guaranty with Woodforest National Bank (effective 2023-02-20).","evidence_excerpt":"In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000017","anchor_url":"https://secwatch.observer/filing/0001420720-23-000017#claim-466d8c37a403e4054bcf6779800b939e5a493b69","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000017/0001420720-23-000017-index.htm"},{"fact_type":"material_agreement","fact_key":"8f53de2822121392852566fb5c08bf0677e5a31e","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-02-21T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Second Amendment to the Guaranty","agreement_type":"credit_facility","counterparty":"Woodforest National Bank","effective_date":"2023-02-09","item_codes_triggered":["1.01"],"value_text":null},"claim":"iBio, Inc. amended Second Amendment to the Guaranty with Woodforest National Bank (effective 2023-02-09).","evidence_excerpt":"On February 9, 2023, the Company, as guarantor, entered into the Second Amendment to the Guaranty, which was executed on November 1, 2021, as amended (the “Guaranty”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000017","anchor_url":"https://secwatch.observer/filing/0001420720-23-000017#claim-8f53de2822121392852566fb5c08bf0677e5a31e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000017/0001420720-23-000017-index.htm"},{"fact_type":"material_agreement","fact_key":"c86cb7de61ba09146e12661b895689097721cd2f","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-02-21T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Third Amendment to the Credit Agreement","agreement_type":"credit_facility","counterparty":"Woodforest National Bank","effective_date":"2023-02-20","item_codes_triggered":["1.01"],"value_text":null},"claim":"iBio, Inc. amended Third Amendment to the Credit Agreement with Woodforest National Bank (effective 2023-02-20).","evidence_excerpt":"On February 20, 2023, iBio CDMO LLC entered into the Third Amendment to the Credit Agreement, which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000017","anchor_url":"https://secwatch.observer/filing/0001420720-23-000017#claim-c86cb7de61ba09146e12661b895689097721cd2f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000017/0001420720-23-000017-index.htm"},{"fact_type":"material_agreement","fact_key":"92076bbe143c2480a39266f9b8bb6e7d9731ac4a","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-02-21T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Second Amendment to the Credit Agreement","agreement_type":"credit_facility","counterparty":"Woodforest National Bank","effective_date":"2023-02-09","item_codes_triggered":["1.01"],"value_text":null},"claim":"iBio, Inc. amended Second Amendment to the Credit Agreement with Woodforest National Bank (effective 2023-02-09).","evidence_excerpt":"On February 9, 2023, iBio CDMO LLC, a wholly owned subsidiary of iBio, Inc. (the “Company”) and Woodforest National Bank (“Woodforest”) entered into the Second Amendment to the Credit Agreement that was entered into on November 1, 2021, as amended (the “Credit Agreement”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-23-000017","anchor_url":"https://secwatch.observer/filing/0001420720-23-000017#claim-92076bbe143c2480a39266f9b8bb6e7d9731ac4a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000017/0001420720-23-000017-index.htm"},{"fact_type":"executive_change","fact_key":"4d02be43e5","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-01-25T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-02-13","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Felipe Duran was appointed as Interim Chief Financial Officer at iBio, Inc..","evidence_excerpt":"and Mr. Felipe Duran, to the position of Interim Chief Financial Officer, effective as of February 13, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-23-000004","anchor_url":"https://secwatch.observer/filing/0001420720-23-000004#claim-4d02be43e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000004/0001420720-23-000004-index.htm"},{"fact_type":"executive_change","fact_key":"5baf892e45","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-01-25T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-01-20","interim":true,"role":"Interim Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Dr. Martin Brenner was appointed as Interim Chief Executive Officer at iBio, Inc..","evidence_excerpt":"appointed Dr. Martin Brenner to the position of Interim Chief Executive Officer, effective immediately","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-23-000004","anchor_url":"https://secwatch.observer/filing/0001420720-23-000004#claim-5baf892e45","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000004/0001420720-23-000004-index.htm"},{"fact_type":"executive_change","fact_key":"573cc15f76","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2023-01-17T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-02-10","interim":false,"role":"Chief Financial and Business Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Robert Lutz resigned as Chief Financial and Business Officer at iBio, Inc..","evidence_excerpt":"On January 11, 2023, Mr. Robert Lutz, the Chief Financial and Business Officer of iBio, Inc. (the “Company”) provided the Company notice of his resignation as an executive officer of the Company, effective February 10, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-23-000002","anchor_url":"https://secwatch.observer/filing/0001420720-23-000002#claim-573cc15f76","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000002/0001420720-23-000002-index.htm"},{"fact_type":"shareholder_vote","fact_key":"49752c8f174c85c6278bdf40e2c9132f038f1b50","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2022-12-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-08","outcome":"passed","proposal_text":"Advisory vote on executive compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,552,791","subject":null,"votes_abstain":"28,727","votes_against":"537,904","votes_for":"780,830","votes_withheld":"0"}]},"claim":"iBio, Inc. shareholders approved Advisory vote on executive compensation at the 2022-12-08 meeting.","evidence_excerpt":"Proposal 3 The stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers (\"say-on-pay\"), as disclosed in the Definitive Proxy Statement. The results of the voting for this approved proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 780,830 537,904 28,727 2,552,791","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001420720-22-000096","anchor_url":"https://secwatch.observer/filing/0001420720-22-000096#claim-49752c8f174c85c6278bdf40e2c9132f038f1b50","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000096/0001420720-22-000096-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a75a8e5288ebba69404d551096d14426c58a9d27","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2022-12-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-08","outcome":"passed","proposal_text":"Ratification of CohnReznick LLP as independent registered public accounting firm for the year ending June 30, 2022","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"66,754","votes_against":"607,132","votes_for":"3,226,366","votes_withheld":"0"}]},"claim":"iBio, Inc. shareholders approved Ratification of CohnReznick LLP as independent registered public accounting firm for the year ending June 30, 2022 at the 2022-12-08 meeting.","evidence_excerpt":"Proposal 2 The stockholders ratified the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the year ending June 30, 2022 based on the votes set forth below: Votes For Votes Against Abstentions Broker Non-Votes 3,226,366 607,132 66,754 0 ​","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001420720-22-000096","anchor_url":"https://secwatch.observer/filing/0001420720-22-000096#claim-a75a8e5288ebba69404d551096d14426c58a9d27","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000096/0001420720-22-000096-index.htm"},{"fact_type":"shareholder_vote","fact_key":"688c40d8de5dedde465203afc04c674efcff02c6","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2022-12-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-08","outcome":"passed","proposal_text":"Election of Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"0","subject":"Dr. Linda W. Armstrong","votes_abstain":"0","votes_against":"0","votes_for":"1,051,212","votes_withheld":"296,249"},{"broker_non_votes":"0","subject":"Dr. Alexandra Kropotova","votes_abstain":"0","votes_against":"0","votes_for":"1,027,547","votes_withheld":"319,914"}]},"claim":"iBio, Inc. shareholders approved Election of Class II directors at the 2022-12-08 meeting.","evidence_excerpt":"Proposal 1 The following two (2) nominees named as Class II directors of the Company’s Board of Directors, each to serve a three-year term expiring at the 2025 Annual Meeting of Stockholders and until such director’s successor is duly elected and qualified, were elected with the following votes: Name of Director Votes For Withheld Broker Non-Votes 1. Dr. Linda W. Armstrong ​ 1,051,212 ​ 296,249 ​ 0 2. Dr. Alexandra Kropotova 1,027,547 319,914 0 ​","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001420720-22-000096","anchor_url":"https://secwatch.observer/filing/0001420720-22-000096#claim-688c40d8de5dedde465203afc04c674efcff02c6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000096/0001420720-22-000096-index.htm"},{"fact_type":"material_agreement","fact_key":"89e395861f5ca457a2ee07a05d0c588ecb61188b","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2022-12-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"H.C. Wainwright & Co., LLC","effective_date":"2022-12-06","item_codes_triggered":["1.01"],"value_text":"approximately $2.9 million"},"claim":"iBio, Inc. entered into Underwriting Agreement with H.C. Wainwright & Co., LLC valued at approximately $2.9 million (effective 2022-12-06).","evidence_excerpt":"On December 6, 2022, iBio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-22-000094","anchor_url":"https://secwatch.observer/filing/0001420720-22-000094#claim-89e395861f5ca457a2ee07a05d0c588ecb61188b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000094/0001420720-22-000094-index.htm"},{"fact_type":"executive_change","fact_key":"22d0d86eb9","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2022-12-07T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-12-01","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Thomas F. Isett resigned as Chief Executive Officer at iBio, Inc..","evidence_excerpt":"Mr. Thomas F. Isett, the Chief Executive Officer (the “CEO”) of iBio, Inc., (the “Company”) and a member of the Board of Directors (the “Board”), and the Company, agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as an officer and the CEO of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-22-000091","anchor_url":"https://secwatch.observer/filing/0001420720-22-000091#claim-22d0d86eb9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000091/0001420720-22-000091-index.htm"},{"fact_type":"executive_change","fact_key":"c7dcb31fb2","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2022-12-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-02","interim":true,"role":"Office of the Chief Executive Officer (joint)","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Martin Brenner was appointed as Office of the Chief Executive Officer (joint) at iBio, Inc..","evidence_excerpt":"the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-22-000086","anchor_url":"https://secwatch.observer/filing/0001420720-22-000086#claim-c7dcb31fb2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000086/0001420720-22-000086-index.htm"},{"fact_type":"executive_change","fact_key":"1f957d0520","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2022-12-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-02","interim":true,"role":"Office of the Chief Executive Officer (joint)","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Robert Lutz was appointed as Office of the Chief Executive Officer (joint) at iBio, Inc..","evidence_excerpt":"the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-22-000086","anchor_url":"https://secwatch.observer/filing/0001420720-22-000086#claim-1f957d0520","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000086/0001420720-22-000086-index.htm"},{"fact_type":"executive_change","fact_key":"6bda94119e","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2022-12-02T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-12-01","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Thomas F. Isett resigned as Chief Executive Officer at iBio, Inc..","evidence_excerpt":"Mr. Isett resigned as CEO of the Company effective December 1, 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-22-000086","anchor_url":"https://secwatch.observer/filing/0001420720-22-000086#claim-6bda94119e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000086/0001420720-22-000086-index.htm"},{"fact_type":"restructuring_charge","fact_key":"333beaf709ea79f14ae81fc4d6fb4abe6219a5e3","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2022-11-03T23:59:59+00:00","payload":{"affected_area":"Company-wide (workforce reduction primarily located at cGMP facility in Bryan, Texas)","charge_text":"approximately $1.7 million","effective_date":"2022-10-31","event_type":"restructuring","headcount_text":"approximately 60% of the current Company staffing levels","item_codes_triggered":["2.05"]},"claim":"iBio, Inc. announced a restructuring with charges of approximately $1.7 million affecting Company-wide (workforce reduction primarily located at cGMP facility in Bryan, Texas) (approximately 60% of the current Company staffing levels).","evidence_excerpt":"2023, although there is no assurance as to when, or for how much, the Company may be able to sell its CDMO assets. The Company expects to incur pre-tax charges of approximately $1.7 million for the employee reduction, most of which is expected to be incurred in the second and third quarter of fiscal year 2023. These charges will be substantially settled in cash and","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001420720-22-000078","anchor_url":"https://secwatch.observer/filing/0001420720-22-000078#claim-333beaf709ea79f14ae81fc4d6fb4abe6219a5e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000078/0001420720-22-000078-index.htm"},{"fact_type":"executive_change","fact_key":"9b76f7868d","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2022-11-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-11-01","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Chip Clark was appointed as Chairman of the Board at iBio, Inc..","evidence_excerpt":"On November 1, 2022, Mr. Chip Clark was appointed as the Company’s Chairman of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-22-000078","anchor_url":"https://secwatch.observer/filing/0001420720-22-000078#claim-9b76f7868d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000078/0001420720-22-000078-index.htm"},{"fact_type":"executive_change","fact_key":"6a257030c6","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2022-05-02T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-05-02","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Randy J. Maddux resigned as Chief Operating Officer at iBio, Inc..","evidence_excerpt":"On April 28, 2022, the Company received the resignation of Randy J. Maddux, its Chief Operating Officer, effective May 2, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001420720-22-000006","anchor_url":"https://secwatch.observer/filing/0001420720-22-000006#claim-6a257030c6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000006/0001420720-22-000006-index.htm"},{"fact_type":"executive_change","fact_key":"61f37051b0","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2021-08-31T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2021-08-26","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Seymour Flug resigned as director at iBio, Inc..","evidence_excerpt":"On August 26, 2021, Seymour Flug resigned as a director of iBio, Inc. (the “Company”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-21-111606","anchor_url":"https://secwatch.observer/filing/0001104659-21-111606#claim-61f37051b0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465921111606/0001104659-21-111606-index.htm"},{"fact_type":"executive_change","fact_key":"256aa9e9ca","cik":1420720,"ticker":"IBIO","company_name":"iBio, Inc.","filed_at":"2021-08-26T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-08-23","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"William D. Clark was elected as Class III Director at iBio, Inc..","evidence_excerpt":"On August 23, 2021, the Board of Directors (the “Board”) of iBio, Inc. (the “Company”) elected William D. (Chip) Clark as a Class III Director of the Board.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-21-109522","anchor_url":"https://secwatch.observer/filing/0001104659-21-109522#claim-256aa9e9ca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465921109522/0001104659-21-109522-index.htm"}]}